Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nitrofurazone

FDA-approved product (ointment, topical), marketed as Actin-N, Furacin, Nitrofurazone.

Registered studies
8
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Nitrofurazone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Eye infection
  • Leishmaniasis
  • Trypanosomiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Antiinfectives; Nitrofuran derivatives; Medicated dressings with antiinfectives; Other antiinfectives
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D08AF01; WHO ATC D09AA03; WHO ATC P01CC02; WHO ATC S01AX04; WHO ATC S02AA02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA9.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae3.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis84.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

8registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nitrofurazone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nitrofurazone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Pit Picking, Phenol and Combined Pit Picking and Phenol Applications in Pilonidal Sinus Treatment

    NCT06517472 · start 2024-10-01

    Registered record
    Registry ID
    NCT06517472
    Conditions
    Pilonidal Sinus
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-10-01
    Completion
    2026-10-01
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPilonidal Sinus
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Creating an Innovative AI-based Technology TCRact for Designing and Optimizing T-cell Receptors (TCR) for Use in Cancer Immunotherapies

    NCT04994093 · start 2021-10-06

    Registered record
    Registry ID
    NCT04994093
    Conditions
    Colon Cancer; Cancer
    Interventions
    Collection of blood (PBMC), biopsy (FFPE) and stool samples.
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-10-06
    Completion
    2023-12-28
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColon Cancer; Cancer
    InterventionCollection of blood (PBMC), biopsy (FFPE) and stool samples.
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Nitrazine in the Treatment of ALS

    NCT04950647 · start 2020-07-01

    Registered record
    Registry ID
    NCT04950647
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    Nitrofurazone Group 1; Nitroketazine Group 2; placebo group
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-07-01
    Completion
    2022-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    InterventionNitrofurazone Group 1; Nitroketazine Group 2; placebo group
    PhasePhase 2
    Registry statusUnknown

  • AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.

    NCT04145232 · start 2019-06-13

    Registered record
    Registry ID
    NCT04145232
    Conditions
    Non Small Cell Lung Cancer; Neoepitopes; Neoantigens; Immunotherapy; Next Generation Sequencing (NGS); Personalized Neoantigen Cancer Vaccine
    Interventions
    Collection of biopsy (FFPE), blood (PBMC) and stool
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-06-13
    Completion
    2020-11-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; Neoepitopes; Neoantigens; Immunotherapy +2 more
    InterventionCollection of biopsy (FFPE), blood (PBMC) and stool
    PhaseNot recorded
    Registry statusUnknown

  • BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

    NCT04136470 · start 2019-04-01

    Registered record
    Registry ID
    NCT04136470
    Conditions
    Non Small Cell Lung Cancer; Microbiome; Metagenome; Immunotherapy; Melanoma
    Interventions
    Collection of stool, blood (PBMC) and biopsy (FFPE)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-04-01
    Completion
    2021-03-31
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; Microbiome; Metagenome; Immunotherapy +1 more
    InterventionCollection of stool, blood (PBMC) and biopsy (FFPE)
    PhaseNot recorded
    Registry statusUnknown

  • Polish Microbiome Map

    NCT04169867 · start 2018-01-01

    Registered record
    Registry ID
    NCT04169867
    Conditions
    Melanoma; Healthy Volunteers; Microbiome; Metagenome; Immunotherapy
    Interventions
    Collection of stool samples
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-01-01
    Completion
    2020-12-31
    Enrolment
    1,160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma; Healthy Volunteers; Microbiome; Metagenome +1 more
    InterventionCollection of stool samples
    PhaseNot recorded
    Registry statusUnknown

  • Patients Response to Early Switch To Oral:Osteomyelitis Study

    NCT02099240 · start 2014-03-06

    Registered record
    Registry ID
    NCT02099240
    Conditions
    Osteomyelitis
    Interventions
    oral antibiotics; intravenous antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2014-03-06
    Completion
    2018-11-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteomyelitis
    Interventionoral antibiotics; intravenous antibiotics
    PhaseEarly phase 1
    Registry statusTerminated

  • Does a Nitrofurazone Coated Bladder Catheter Reduce the Number of Urinary Tract Infections in Trauma

    NCT00192985 · start 2003-05

    Registered record
    Registry ID
    NCT00192985
    Conditions
    Trauma; Urinary Tract Infections
    Interventions
    Nitrofuranzone coated bladder catheter
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2003-05
    Completion
    2006-09
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrauma; Urinary Tract Infections
    InterventionNitrofuranzone coated bladder catheter
    PhasePhase 3
    Registry statusUnknown